2008
DOI: 10.1016/j.ejca.2008.01.028
|View full text |Cite
|
Sign up to set email alerts
|

Pegylated liposomal doxorubicin-associated hand–foot syndrome: Recommendations of an international panel of experts

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
70
0
5

Year Published

2011
2011
2023
2023

Publication Types

Select...
5
3

Relationship

1
7

Authors

Journals

citations
Cited by 113 publications
(75 citation statements)
references
References 50 publications
0
70
0
5
Order By: Relevance
“…It seems necessary to develop a health-related QoL scale enabling investigators to independently assess the effects of anticancer treatment and the effects of the cancer itself on QoL. Besides, additional research is needed to determine to what extent HFS prevention and treatment strategies could alter the QoL of cancer patients with HFS [10,11,14].…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…It seems necessary to develop a health-related QoL scale enabling investigators to independently assess the effects of anticancer treatment and the effects of the cancer itself on QoL. Besides, additional research is needed to determine to what extent HFS prevention and treatment strategies could alter the QoL of cancer patients with HFS [10,11,14].…”
Section: Discussionmentioning
confidence: 99%
“…Several experts highlighted the importance of properly assessing QoL in combination with therapeutic efficacy to help determine the most effective HFS management strategies in patients treated for cancer [9,10,11,14]. If appropriate management is not rapidly implemented, HFS may worsen and QoL impairment may lead to anticancer treatment modification or discontinuation, with the risk for potentially limiting its efficacy [3,23].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…However, in clinical practice the administration of PEGylated liposomes loaded with doxorubicin was associated with palmar-plantar erythrodysesthesia ("hand-foot" syndrome), which may evolve into ulceration and epidermal necrosis if the chemotherapy cycle is not delayed (19). Hand-foot syndrome represents a major limitation in the Caelyx treatment, because it can adversely affect the quality of life of the patients, which may be addressed by dose-reduction strategy (20). In addition, recent studies have demonstrated that PEGylated liposomes can generate complement activation through increased alternative pathway turnover (21), which now provides a plausible explanation to the previously reported anaphylaxis, or is referred to as cardiovascular collapse in species that have received medicines containing poly (ethylene glycol) as a carrier/solubilizer (22).…”
Section: Significancementioning
confidence: 99%
“…Some of these agents including celecoxib have demonstrated promising effects in subsets of patients [17], but require further research to substantiate preliminary findings. Research in non-pharmacologic intervention for the prevention or treatment of HFS is limited, resulting in an inability to establish effectiveness [18].…”
Section: Introductionmentioning
confidence: 99%